RARE vs VTAK · rev $350.0M vs rev $1.5M
Ultragenyx (RARE) versus Catheter Precision Inc. (VTAK) — a side-by-side from cached financials, not a winner call.
Ultragenyx (RARE) is a biotechnology company listed on US.
Catheter Precision Inc. (VTAK) is a medical devices company listed on US.
Latest reported RARE revenue for 2026-06-30 was $350.0M. Net income was -$277.0M. RARE currently screens at market cap $2.79B.
Latest reported VTAK revenue for 2026-06-30 was $1.5M. Net income was -$5.0M. VTAK currently screens at market cap $3.0M.
RARE currently screens at market cap $2.79B. VTAK currently screens at market cap $3.0M.
Not investment advice. Open the RARE and VTAK stock pages for the full models.
Not investment advice.